Fosun Pharma Announces HK$1 Billion Share Repurchase Plan

SHANGHAI, Sept. 6, 2026 /CourierPR/ -- Shanghai Fosun Pharmaceutical (Group) Co., Ltd., commonly known as Fosun Pharma, announced on [date] a plan to repurchase up to HK$1 billion worth of its Hong Kong-listed H-shares. The repurchased shares will be either canceled or held as treasury shares. This move, which was put into effect promptly, aims to address market concerns and convey the company's confidence in its intrinsic value.

According to Fosun Pharma, the repurchase plan is part of the company's ongoing efforts to manage shareholder value. It will be implemented on a rolling basis, allowing Fosun Pharma to react to changing market conditions. The repurchase will be funded primarily by the proceeds from the sale of approximately 6.00% of Fosun Pharma's equity interest in Gland Pharma, valued at around US$294 million. Upon the sale, Fosun Pharma will retain a controlling stake in Gland Pharma, with a shareholding of about 45.76%. The net proceeds from this transaction will be directed towards research and development (R&D) investments, share repurchases, and debt repayment.

In the first half of 2026, Fosun Pharma reported an improvement in its earnings quality, with revenue from innovative drugs and international markets steadily increasing. The company's financial performance for the first half of 2026 showed a significant year-over-year growth in several key metrics: - Revenue increased by 4.75% to RMB 20,442 million. - Net profit attributable to shareholders of the listed company, net of non-recurring gains and losses, rose by 19.09% to RMB 1,144 million. - Net cash generated from operating activities increased by 13.59% to RMB 2,424 million.

Fosun Pharma intends to continue its focus on innovation and globalization, accelerating the R&D progress and commercialization of its major pipeline candidates. The share repurchase program is seen as a way to enhance shareholder returns and demonstrate the company's belief in its long-term prospects.

"The repurchase plan is a clear indication of our commitment to creating sustainable value for shareholders," said a spokesperson for Fosun Pharma. "We are confident in the future of our company and are taking proactive steps to ensure our continued growth and success."

The repurchase plan is part of Fosun Pharma's broader strategy to manage its share structure and enhance shareholder returns. It reflects the company's confidence in its intrinsic value and its ongoing commitment to shareholder value creation.